252 related articles for article (PubMed ID: 28697165)
1. Association of CYP3A5 Expression and Vincristine Neurotoxicity in Pediatric Malignancies in Turkish Population.
Kayilioğlu H; Kocak U; Kan Karaer D; Percin EF; Sal E; Tekkesin F; Isik M; Oner N; Belen FB; Yilmaz Keskin E; Okur A; Albayrak M; Kaya Z; Pinarli FG; Yenicesu I; Karadeniz C; Oguz A; Gursel T
J Pediatr Hematol Oncol; 2017 Aug; 39(6):458-462. PubMed ID: 28697165
[TBL] [Abstract][Full Text] [Related]
2. Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia.
Egbelakin A; Ferguson MJ; MacGill EA; Lehmann AS; Topletz AR; Quinney SK; Li L; McCammack KC; Hall SD; Renbarger JL
Pediatr Blood Cancer; 2011 Mar; 56(3):361-7. PubMed ID: 21225912
[TBL] [Abstract][Full Text] [Related]
3. The effect of race on the CYP3A-mediated metabolism of vincristine in pediatric patients with acute lymphoblastic leukemia.
Sims RP
J Oncol Pharm Pract; 2016 Feb; 22(1):76-81. PubMed ID: 25305360
[TBL] [Abstract][Full Text] [Related]
4. Impact of plasma and intracellular exposure and CYP3A4, CYP3A5, and ABCB1 genetic polymorphisms on vincristine-induced neurotoxicity.
Guilhaumou R; Solas C; Bourgarel-Rey V; Quaranta S; Rome A; Simon N; Lacarelle B; Andre N
Cancer Chemother Pharmacol; 2011 Dec; 68(6):1633-8. PubMed ID: 21968951
[TBL] [Abstract][Full Text] [Related]
5. Vincristine pharmacodynamics and pharmacogenetics in children with cancer: a limited-sampling, population modelling approach.
Moore AS; Norris R; Price G; Nguyen T; Ni M; George R; van Breda K; Duley J; Charles B; Pinkerton R
J Paediatr Child Health; 2011 Dec; 47(12):875-82. PubMed ID: 21658147
[TBL] [Abstract][Full Text] [Related]
6. Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients.
Renbarger JL; McCammack KC; Rouse CE; Hall SD
Pediatr Blood Cancer; 2008 Apr; 50(4):769-71. PubMed ID: 18085684
[TBL] [Abstract][Full Text] [Related]
7. Incidence of vincristine induced neurotoxicity in children with acute lymphoblastic leukemia and its correlation with nutritional deficiencies.
Dudeja S; Gupta S; Sharma S; Jain A; Sharma S; Jain P; Aneja S; Chandra J
Pediatr Hematol Oncol; 2019 Sep; 36(6):344-351. PubMed ID: 31514565
[TBL] [Abstract][Full Text] [Related]
8. CYP3A5 genotype and its impact on vincristine pharmacokinetics and development of neuropathy in Kenyan children with cancer.
Skiles JL; Chiang C; Li CH; Martin S; Smith EL; Olbara G; Jones DR; Vik TA; Mostert S; Abbink F; Kaspers GJ; Li L; Njuguna F; Sajdyk TJ; Renbarger JL
Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29115708
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Toxicity of Vincristine and CYP3A5 Genetic Polymorphism in Rhabdomyosarcoma Pediatric Egyptian Patients.
Shalaby N; Zaki HF; Badary OA; Kamal S; Nagy M; Makhlouf D; Elnashar A; Elnadi E; Abdelshafi SA; Abouelnaga S; Saber MM
Asian Pac J Cancer Prev; 2024 Apr; 25(4):1391-1409. PubMed ID: 38680001
[TBL] [Abstract][Full Text] [Related]
10. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia.
Diouf B; Crews KR; Lew G; Pei D; Cheng C; Bao J; Zheng JJ; Yang W; Fan Y; Wheeler HE; Wing C; Delaney SM; Komatsu M; Paugh SW; McCorkle JR; Lu X; Winick NJ; Carroll WL; Loh ML; Hunger SP; Devidas M; Pui CH; Dolan ME; Relling MV; Evans WE
JAMA; 2015 Feb; 313(8):815-23. PubMed ID: 25710658
[TBL] [Abstract][Full Text] [Related]
11. Variants in vincristine pharmacodynamic genes involved in neurotoxicity at induction phase in the therapy of pediatric acute lymphoblastic leukemia.
Martin-Guerrero I; Gutierrez-Camino A; Echebarria-Barona A; Astigarraga I; Garcia de Andoin N; Navajas A; Garcia-Orad A
Pharmacogenomics J; 2019 Dec; 19(6):564-569. PubMed ID: 30723315
[TBL] [Abstract][Full Text] [Related]
12. Severe Vincristine-related Neurotoxicity in 5 Patients With Pediatric Acute Lymphoblastic Leukemia Requiring Discontinuation of Vincristine: A Description of Long-term Outcome.
Egan-Sherry D; Bhuta R; Cole PD; Gennarini LM; Kahn JM; Sulis ML; DeNardo BD; Welch JJG
J Pediatr Hematol Oncol; 2021 Oct; 43(7):e997-e999. PubMed ID: 34001785
[TBL] [Abstract][Full Text] [Related]
13. Effects of cytochrome P450 family 3 subfamily A member 5 gene polymorphisms on daunorubicin metabolism and adverse reactions in patients with acute leukemia.
Huang Z; Wang J; Qian J; Li Y; Xu Z; Chen M; Tong H
Mol Med Rep; 2017 Jun; 15(6):3493-3498. PubMed ID: 28440407
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetic association with neurotoxicity in Hispanic children with acute lymphoblastic leukaemia.
McClain CA; Bernhardt MB; Berger A; Bernini JC; Marquez-Do D; Winslow R; Scheurer ME; Schafer ES
Br J Haematol; 2018 Jun; 181(5):684-687. PubMed ID: 28419449
[No Abstract] [Full Text] [Related]
15. Vincristine-induced peripheral neuropathy in survivors of childhood acute lymphoblastic leukaemia.
Tay CG; Lee VWM; Ong LC; Goh KJ; Ariffin H; Fong CY
Pediatr Blood Cancer; 2017 Aug; 64(8):. PubMed ID: 28139029
[TBL] [Abstract][Full Text] [Related]
16. Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia.
Ceppi F; Langlois-Pelletier C; Gagné V; Rousseau J; Ciolino C; De Lorenzo S; Kevin KM; Cijov D; Sallan SE; Silverman LB; Neuberg D; Kutok JL; Sinnett D; Laverdière C; Krajinovic M
Pharmacogenomics; 2014 Jun; 15(8):1105-16. PubMed ID: 25084203
[TBL] [Abstract][Full Text] [Related]
17. The impact of CYP3A5*3 on risk and prognosis in childhood acute lymphoblastic leukemia.
Borst L; Wallerek S; Dalhoff K; Rasmussen KK; Wesenberg F; Wehner PS; Schmiegelow K
Eur J Haematol; 2011 Jun; 86(6):477-83. PubMed ID: 21418106
[TBL] [Abstract][Full Text] [Related]
18. Identification of a less toxic vinca alkaloid derivative for use as a chemotherapeutic agent, based on in silico structural insights and metabolic interactions with CYP3A4 and CYP3A5.
Saba N; Seal A
J Mol Model; 2018 Mar; 24(4):82. PubMed ID: 29502215
[TBL] [Abstract][Full Text] [Related]
19. Vincristine pharmacokinetics pathway and neurotoxicity during early phases of treatment in pediatric acute lymphoblastic leukemia.
Lopez-Lopez E; Gutierrez-Camino A; Astigarraga I; Navajas A; Echebarria-Barona A; Garcia-Miguel P; Garcia de Andoin N; Lobo C; Guerra-Merino I; Martin-Guerrero I; Garcia-Orad A
Pharmacogenomics; 2016 May; 17(7):731-41. PubMed ID: 27180762
[TBL] [Abstract][Full Text] [Related]
20. Potentiation of vincristine toxicity by itraconazole in children with lymphoid malignancies.
Kamaluddin M; McNally P; Breatnach F; O'Marcaigh A; Webb D; O'Dell E; Scanlon P; Butler K; O'Meara A
Acta Paediatr; 2001 Oct; 90(10):1204-7. PubMed ID: 11697438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
